Oligo

Developing new tools in the pandemic response toolbox

There’s a lot to be learned from the COVID-19 pandemic, including how we can be better prepared for future pandemics.

The ideal pandemic response must include a pharmaceutical approach, both vaccines to prevent new infections and treatments to address those infected.

This presentation will discuss how new siRNA and mRNA modalities could be deployed as treatments and as vaccines respectively, and the potential advantages they could offer to traditional approaches. The ongoing efforts to develop these therapies for COVID-19 will be discussed as well as the presently existing hurdles. If COVID-19 has come too early for these platforms to reach their infectious disease-fighting potential, then it should serve as the start of the development process, not the end.

“The old ways are not bad; I'm just asking, 'Could they be better?'”

The ideal characteristics of a pharmaceutical response to a pandemic:

  • Rapid development time
  • Rapid deployment time
  • Efficacy, but not at the expense of safety
  • Specificity, but not at the expense of flexibility
  • Stability/shelf-life

It is possible that new modalities will meet these characteristics better than established vaccines. Watch the webinar to learn how.

Please enter your contact information to access the webinar.
 Return to top

Related Content

COVID-19

Keys to accelerating your COVID-19 drug campaign

At CRB, we have the experience, the tools, and the flexibility to help your facility respond to pandemic response production to reliable, commercial-scale capacity as fast as possible.

Read More